Editing In vitro fertilisation (section)

===Luteal support===
{{Main|Luteal support}}
[[Luteal support]] is the administration of medication, generally [[progesterone]], [[progestin]]s, hCG, or [[GnRH agonist]]s, and often accompanied by estradiol, to increase the success rate of [[Implantation (human embryo)|implantation]] and early [[Human embryogenesis|embryogenesis]], thereby complementing and/or supporting the function of the [[corpus luteum]]. A Cochrane review found that hCG or progesterone given during the luteal phase may be associated with higher rates of [[Live birth rate|live birth]] or ongoing pregnancy, but that the evidence is not conclusive.<ref name="van-der-Linden2011">{{cite journal | vauthors = van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M | title = Luteal phase support for assisted reproduction cycles | journal = The Cochrane Database of Systematic Reviews | volume = 2015 | issue = 7 | pages = CD009154 | date = July 2015 | pmid = 26148507 | pmc = 6461197 | doi = 10.1002/14651858.CD009154.pub3 | hdl = 2066/98072 }}</ref> Co-treatment with [[GnRH agonist]]s appears to improve outcomes,<ref name=van-der-Linden2011/> by a live birth rate [[risk difference|RD]] of +16% (95% [[confidence interval]] +10 to +22%).<ref>{{cite journal | vauthors = Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzi TB, Devroey P, Tarlatzis BC | title = Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a systematic review and meta-analysis | journal = Human Reproduction Update | volume = 17 | issue = 6 | pages = 734–740 | year = 2011 | pmid = 21733980 | doi = 10.1093/humupd/dmr029 | doi-access = free }}</ref> On the other hand, [[growth hormone]] or [[aspirin]] as adjunctive medication in IVF have no evidence of overall benefit.<ref name=":0" />